An international research team led by the University of Oxford developed a blood test that can detect molecular signals for 19 different cancer types [1].

Early detection is critical for improving patient survival rates, particularly for aggressive diseases like lung cancer. Identifying risks before physical symptoms manifest allows for earlier intervention and more effective treatment strategies [1, 2].

According to the research published in Nature Communications in 2024, the test identifies specific molecular markers in the blood [1]. These signals may indicate a risk of developing cancer up to seven years before symptoms appear [1]. The study was conducted by an international consortium based at the University of Oxford in the United Kingdom [1].

The test focuses on molecular signals rather than existing tumors. This approach aims to shift the diagnostic window, allowing clinicians to monitor high-risk individuals long before a malignancy is visible on traditional imaging [2].

Despite the potential of the findings, the scientific community remains divided on the current viability of such tests. Some reports said that blood tests promising to detect multiple types of cancer are still considered by some experts to lack sufficient scientific backing [3].

The Oxford team designed the tool to specifically target the early molecular changes that precede tumor growth. By focusing on 19 distinct types of cancer, the researchers said they hope to create a broad screening tool that could eventually be integrated into routine healthcare checkups [1].

“The test can detect signals of 19 different cancer types.”

This research represents a shift toward predictive oncology, moving from diagnosing existing tumors to identifying biological predispositions. While the seven-year lead time offers a significant window for prevention, the contradiction between the study's results and broader scientific skepticism suggests the technology is likely in a validation phase and not yet ready for widespread clinical application.